RxDoctor Payments DataLook up a doctor →

Gregory San, MD

Cardiovascular Disease · Greenville, SCNPI 1679565279

Payments from drug & device makers

$429,234in general payments, 2019–2025

Across 744 payments — averaging $576.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$226K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$115K
  • Lilly USA, LLC$49K
  • Boehringer Ingelheim$30K
  • Boston Scientific$1K
  • Medtronic$878
  • plus $7K from 30 others

What the payments were for

  • Consulting fees$3,7504%
  • Speaking & faculty fees$70,09880%
  • Travel & lodging$3,1934%
  • Food & beverage$10,85112%
  • Education$940%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$429,234 in reported general payments places this provider in the 95th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$278,861
Medicare patients
1,019
Services billed
4,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban550$586,886
XareltoRivaroxaban217$249,870
JardianceEmpagliflozin245$236,962
Repatha SureclickEvolocumab151$139,065
EntrestoSacubitril/Valsartan122$121,802
OzempicSemaglutide97$95,410
WegovySemaglutide36$55,662
FarxigaDapagliflozin Propanediol35$39,000
MounjaroTirzepatide21$21,489
BrilintaTicagrelor12$11,332
VascepaIcosapent Ethyl15$8,568
Valsartan271$8,074
Metoprolol Succinate612$7,841
NexlizetBempedoic Acid/Ezetimibe13$6,707
Ranolazine ErRanolazine48$5,479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$384$586,886550 claims
Johnson & JohnsonXarelto$854$249,870217 claims
Boehringer IngelheimJardiance$29,802$236,962245 claims
Novo NordiskOzempic, Wegovy$38$151,072133 claims
NovartisEntresto$652$121,802122 claims
AstraZenecaFarxiga, Brilinta$393$50,33147 claims
Lilly USA, LLCMounjaro$49,306$21,48921 claims
Esperion Therapeutics, Inc.Nexlizet$34$6,70713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →